BCTX
Closed
Briacell Therapeutics Corp
2.86
-0.08 (-2.72%)
Last Update: 01 Jul 2025 23:02:00
Yesterday: 2.94
Day's Range: 2.85 - 2.95
Send
sign up or login to leave a comment!
When Written:
7.45
BriaCell Therapeutics Corp is a clinical-stage biotechnology company that develops targeted immunotherapies for advanced breast cancer and other cancers. The company's lead product candidate, Bria-IMT, is a personalized immunotherapy that targets cancer cells while sparing healthy cells. BriaCell also has a second product candidate, Bria-OTS, which is a off-the-shelf immunotherapy that is designed to work in combination with Bria-IMT.
BriaCell's immunotherapies are based on a proprietary technology platform that leverages the patient's own immune system to fight cancer. The company's approach is to stimulate an immune response against cancer cells by exposing the patient's immune system to cancer-specific antigens. This approach has the potential to be more effective and less toxic than traditional chemotherapy and radiation therapy.
BriaCell is headquartered in Berkeley, California, and has additional operations in Vancouver, British Columbia. The company was founded in 2014 and went public in 2017.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
BriaCell's immunotherapies are based on a proprietary technology platform that leverages the patient's own immune system to fight cancer. The company's approach is to stimulate an immune response against cancer cells by exposing the patient's immune system to cancer-specific antigens. This approach has the potential to be more effective and less toxic than traditional chemotherapy and radiation therapy.
BriaCell is headquartered in Berkeley, California, and has additional operations in Vancouver, British Columbia. The company was founded in 2014 and went public in 2017.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








